Background Direct‐acting anti‐virals (DAAs) licensed to treat chronic HCV infection have
revolutionised treatment algorithms by drastically mitigating side effects while enhancing …

Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and
chronic liver disease worldwide. Over the past decades many immunological studies …

BACKGROUND. Hepatitis C virus (HCV) infects approximately 170 million people worldwide
and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals …

Interferon (IFN) is widely recognised to be an integral part of the innate immune response to
viral infection. Since its initial discovery in 1957 by Isaacs and Lindenmann, various IFN sub …

Ribavirin has been used as an antiviral agent for several decades. Although it has activity
against numerous viruses, its major use clinically has been in the treatment of respiratory …

Roughly 20 years after the discovery of the hepatitis C virus (HCV), and 10 years after the
launch of the current standard of care (SOC) therapy, ie the combination of pegylated …

The combination of pegylated interferon (PEG‐IFN) and ribavirin is the standard treatment
for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the …

The increasing incidence of hepatitis C virus (HCV) infections underscores the need for an
effective vaccine. Successful vaccines to other viruses generally depend on a long-lasting …

Mathematically modelling changes in HCV RNA levels measured in patients who receive
antiviral therapy has yielded many insights into the pathogenesis and effects of treatment on …

Background: Cirrhosis developing during chronic infection with the hepatitis C virus (HCV)
poses a risk of anticipated liver-related death, therefore representing a dominant indication …